A. Wells (London, United Kingdom), K. Antoniou (Heraklion, Crete, Greece)
Extracorporeal membrane oxygenation for the treatment of acute exacerbation of interstitial lung diseases
S. Ohshimo (Hiroshima, Japan)
|    |
Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data
K. Karagiannis (Rhodes, Greece)
| |
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
U. Costabel (Essen, Germany)
|  |
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients
L. Richeldi (Southampton, United Kingdom)
| |
Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials
S. Nathan (Falls Church, United States of America)
| |
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON
B. Crestani (Paris, France)
| |
Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF)
A. Wells (London, United Kingdom)
| |